MedTrace Logo

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

NCT00089440 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-01-11

No results posted yet for this study

Summary

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

Conditions

  • Amphetamine-Related Disorders

Interventions

DRUG

Aripiprazole

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Thomas Newton, M.D. · University of California, Los Angeles

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089440 on ClinicalTrials.gov